Here, we hypothesized that combining menin inhibitors with other epigenetic-modifying drugs would synergistically disrupt leukemogenic transcriptional programs and enforce stable differentiation, thereby yielding more durable therapeutic responses in MLL-r AML. Here, MEN1 is linked to acute myeloid leukemia.